Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Debt Ratios
Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The solvency profile demonstrates a distinct structural shift occurring between April 2023 and December 2023, characterized by a significant increase across all measured leverage ratios. Prior to this period, the organization maintained a conservative solvency posture; however, subsequent quarters indicate a sustained increase in the reliance on debt financing, which remained elevated through September 2026.
- Debt to Equity
- A period of relative stability and slight decline is observed from April 2022 to April 2023, with the ratio moving from 0.44 to 0.36. A sharp escalation began in July 2023, reaching a peak of 0.81 by December 2023. From 2024 through 2026, the ratio fluctuated within a higher corridor, generally stabilizing between 0.66 and 0.75, indicating a permanent increase in the debt-to-equity mix compared to the 2022 baseline.
- Debt to Capital
- The debt to capital ratio mirrors the trend seen in debt to equity, decreasing from 0.31 in early 2022 to a low of 0.26 in April 2023. A subsequent rise is noted, peaking at 0.45 in December 2023. For the remainder of the analyzed period, the ratio remained consistently higher than the initial baseline, oscillating narrowly between 0.40 and 0.44.
- Debt to Assets
- The ratio of debt to assets remained stable between 0.18 and 0.21 during the first year of analysis. A significant step-up occurred in July 2023, where the ratio climbed to 0.30. This level remained remarkably consistent from mid-2023 through September 2026, with only minor deviations between 0.30 and 0.32, suggesting a strategic shift in the asset funding structure.
- Financial Leverage
- Financial leverage exhibited a downward trend in the first year, reaching a minimum of 1.94 in April 2023. This was followed by a rapid increase to a peak of 2.54 by December 2023. The metric then entered a period of volatility, fluctuating between 2.25 and 2.47 throughout 2024, 2025, and 2026, reflecting a more aggressive leverage position than that maintained in early 2023.
In summary, the data indicates a coordinated increase in solvency ratios starting in the second quarter of 2023. The synchronization of these increases suggests a deliberate expansion of the debt load, which has since transitioned from a growth phase to a plateau of higher sustained leverage.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Debt to Equity
| Sep 27, 2026 | Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings, including current portion of long-term debt | 2,674) | 2,699) | 3,890) | 3,154) | 4,303) | 4,295) | 4,470) | 6,946) | 9,699) | 11,944) | 8,232) | 10,350) | 2,548) | 3,985) | 4,188) | 2,945) | 4,040) | 5,990) | 645) | ||||||
| Long-term debt, excluding current portion | 59,997) | 60,495) | 60,565) | 61,641) | 57,409) | 57,502) | 57,639) | 57,405) | 58,002) | 57,506) | 61,307) | 61,538) | 61,048) | 61,356) | 31,704) | 32,884) | 32,629) | 34,294) | 35,656) | ||||||
| Total debt | 62,671) | 63,194) | 64,455) | 64,795) | 61,712) | 61,797) | 62,109) | 64,351) | 67,701) | 69,450) | 69,539) | 71,888) | 63,596) | 65,341) | 35,892) | 35,829) | 36,669) | 40,284) | 36,301) | ||||||
| Total Pfizer Inc. shareholders’ equity | 89,001) | 85,190) | 90,101) | 86,476) | 92,801) | 88,695) | 90,338) | 88,203) | 92,286) | 87,700) | 92,282) | 89,014) | 96,934) | 99,019) | 100,970) | 95,661) | 92,631) | 87,208) | 82,424) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | 0.70 | 0.74 | 0.72 | 0.75 | 0.66 | 0.70 | 0.69 | 0.73 | 0.73 | 0.79 | 0.75 | 0.81 | 0.66 | 0.66 | 0.36 | 0.37 | 0.40 | 0.46 | 0.44 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | 49.22 | 20.19 | 11.78 | 10.42 | 9.24 | 5.73 | 5.02 | 4.74 | 4.68 | 3.67 | 4.35 | 4.98 | 4.51 | ||||||
| Amgen Inc. | 3.76 | 4.90 | 6.24 | 6.31 | 5.67 | 7.57 | 9.24 | 10.23 | 8.02 | 10.57 | 12.75 | 10.37 | 7.90 | 9.08 | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | ||||||
| Bristol-Myers Squibb Co. | 1.83 | 1.93 | 2.22 | 2.44 | 2.64 | 2.82 | 2.86 | 3.04 | 2.90 | 3.08 | 3.38 | 1.35 | 1.30 | 1.18 | 1.19 | 1.27 | 1.20 | 1.29 | 1.42 | ||||||
| Danaher Corp. | 0.49 | 0.51 | 0.35 | 0.35 | 0.33 | 0.33 | 0.32 | 0.32 | 0.34 | 0.34 | 0.34 | 0.34 | 0.42 | 0.38 | 0.39 | 0.39 | 0.41 | 0.43 | 0.47 | ||||||
| Eli Lilly & Co. | 1.23 | 1.62 | 1.39 | 1.60 | 1.79 | 2.18 | 2.44 | 2.37 | 2.19 | 2.13 | 2.05 | 2.34 | 1.80 | 1.70 | 1.69 | 1.52 | 1.58 | 1.97 | 1.77 | ||||||
| Gilead Sciences Inc. | 2.01 | 2.22 | 0.94 | 1.10 | 1.16 | 1.27 | 1.30 | 1.38 | 1.26 | 1.28 | 1.44 | 1.09 | 1.12 | 1.19 | 1.20 | 1.19 | 1.20 | 1.30 | 1.32 | ||||||
| Johnson & Johnson | 0.55 | 0.58 | 0.68 | 0.59 | 0.58 | 0.65 | 0.67 | 0.51 | 0.51 | 0.58 | 0.48 | 0.43 | 0.42 | 0.61 | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | ||||||
| Merck & Co. Inc. | 1.20 | 1.29 | 1.07 | 0.94 | 0.80 | 0.72 | 0.72 | 0.80 | 0.86 | 0.87 | 0.85 | 0.93 | 0.85 | 0.95 | 0.66 | 0.67 | 0.68 | 0.73 | 0.78 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | ||||||
| Thermo Fisher Scientific Inc. | 0.76 | 0.81 | 0.83 | 0.74 | 0.70 | 0.70 | 0.69 | 0.63 | 0.72 | 0.75 | 0.78 | 0.75 | 0.78 | 0.78 | 0.83 | 0.78 | 0.67 | 0.72 | 0.81 | ||||||
| Vertex Pharmaceuticals Inc. | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q3 2026 Calculation
Debt to equity = Total debt ÷ Total Pfizer Inc. shareholders’ equity
= 62,671 ÷ 89,001 = 0.70
2 Click competitor name to see calculations.
The solvency profile exhibits a distinct shift in leverage starting in mid-2023, moving from a conservative capital structure to a more leveraged position that remains elevated through the end of the observed period.
- Total Debt Trends
- Between April 2022 and April 2023, total debt remained relatively stable, fluctuating between US$ 35.8 billion and US$ 40.2 billion. A substantial increase occurred in July 2023, where debt rose to US$ 65.3 billion, eventually peaking at US$ 71.8 billion in December 2023. From January 2024 onward, a gradual deleveraging trend is observed, with total debt decreasing to US$ 62.6 billion by September 2026.
- Shareholders' Equity Fluctuations
- Equity demonstrated a consistent upward trajectory from April 2022 (US$ 82.4 billion) to a peak of US$ 100.9 billion in April 2023. Following this peak, equity levels entered a period of volatility, generally oscillating between US$ 85 billion and US$ 92 billion. The equity base concluded the period at US$ 89 billion in September 2026.
- Debt to Equity Ratio Analysis
- The debt to equity ratio initially trended downward, reaching a minimum of 0.36 in April 2023. This was followed by a sharp increase to 0.66 in July 2023 and a peak of 0.81 in December 2023, correlating with the surge in total debt. Throughout the subsequent quarters, the ratio stabilized, fluctuating between 0.66 and 0.75, and ending at 0.70 in September 2026.
The transition from a low-leverage environment in 2022 and early 2023 to a higher-leverage environment from late 2023 onward suggests a strategic shift in financing or a significant capital expenditure event. While the peak leverage observed in December 2023 has since moderated, the long-term solvency position has settled at a higher debt-to-equity baseline than that maintained during the first year of the analysis.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Debt to Capital
| Sep 27, 2026 | Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings, including current portion of long-term debt | 2,674) | 2,699) | 3,890) | 3,154) | 4,303) | 4,295) | 4,470) | 6,946) | 9,699) | 11,944) | 8,232) | 10,350) | 2,548) | 3,985) | 4,188) | 2,945) | 4,040) | 5,990) | 645) | ||||||
| Long-term debt, excluding current portion | 59,997) | 60,495) | 60,565) | 61,641) | 57,409) | 57,502) | 57,639) | 57,405) | 58,002) | 57,506) | 61,307) | 61,538) | 61,048) | 61,356) | 31,704) | 32,884) | 32,629) | 34,294) | 35,656) | ||||||
| Total debt | 62,671) | 63,194) | 64,455) | 64,795) | 61,712) | 61,797) | 62,109) | 64,351) | 67,701) | 69,450) | 69,539) | 71,888) | 63,596) | 65,341) | 35,892) | 35,829) | 36,669) | 40,284) | 36,301) | ||||||
| Total Pfizer Inc. shareholders’ equity | 89,001) | 85,190) | 90,101) | 86,476) | 92,801) | 88,695) | 90,338) | 88,203) | 92,286) | 87,700) | 92,282) | 89,014) | 96,934) | 99,019) | 100,970) | 95,661) | 92,631) | 87,208) | 82,424) | ||||||
| Total capital | 151,672) | 148,384) | 154,556) | 151,271) | 154,513) | 150,492) | 152,447) | 152,554) | 159,987) | 157,150) | 161,821) | 160,902) | 160,530) | 164,360) | 136,862) | 131,490) | 129,300) | 127,492) | 118,725) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | 0.41 | 0.43 | 0.42 | 0.43 | 0.40 | 0.41 | 0.41 | 0.42 | 0.42 | 0.44 | 0.43 | 0.45 | 0.40 | 0.40 | 0.26 | 0.27 | 0.28 | 0.32 | 0.31 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 1.06 | 1.09 | 1.10 | 1.05 | 1.04 | 1.00 | 0.98 | 0.95 | 0.92 | 0.91 | 0.90 | 0.85 | 0.83 | 0.83 | 0.82 | 0.79 | 0.81 | 0.83 | 0.82 | ||||||
| Amgen Inc. | 0.79 | 0.83 | 0.86 | 0.86 | 0.85 | 0.88 | 0.90 | 0.91 | 0.89 | 0.91 | 0.93 | 0.91 | 0.89 | 0.90 | 0.92 | 0.91 | 0.91 | 0.94 | 0.98 | ||||||
| Bristol-Myers Squibb Co. | 0.65 | 0.66 | 0.69 | 0.71 | 0.73 | 0.74 | 0.74 | 0.75 | 0.74 | 0.75 | 0.77 | 0.57 | 0.56 | 0.54 | 0.54 | 0.56 | 0.54 | 0.56 | 0.59 | ||||||
| Danaher Corp. | 0.33 | 0.34 | 0.26 | 0.26 | 0.25 | 0.25 | 0.24 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.30 | 0.28 | 0.28 | 0.28 | 0.29 | 0.30 | 0.32 | ||||||
| Eli Lilly & Co. | 0.55 | 0.62 | 0.58 | 0.62 | 0.64 | 0.69 | 0.71 | 0.70 | 0.69 | 0.68 | 0.67 | 0.70 | 0.64 | 0.63 | 0.63 | 0.60 | 0.61 | 0.66 | 0.64 | ||||||
| Gilead Sciences Inc. | 0.67 | 0.69 | 0.49 | 0.52 | 0.54 | 0.56 | 0.57 | 0.58 | 0.56 | 0.56 | 0.59 | 0.52 | 0.53 | 0.54 | 0.55 | 0.54 | 0.54 | 0.56 | 0.57 | ||||||
| Johnson & Johnson | 0.35 | 0.37 | 0.40 | 0.37 | 0.37 | 0.39 | 0.40 | 0.34 | 0.34 | 0.37 | 0.32 | 0.30 | 0.30 | 0.38 | 0.43 | 0.34 | 0.30 | 0.30 | 0.31 | ||||||
| Merck & Co. Inc. | 0.55 | 0.56 | 0.52 | 0.48 | 0.44 | 0.42 | 0.42 | 0.44 | 0.46 | 0.46 | 0.46 | 0.48 | 0.46 | 0.49 | 0.40 | 0.40 | 0.41 | 0.42 | 0.44 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | ||||||
| Thermo Fisher Scientific Inc. | 0.43 | 0.45 | 0.45 | 0.42 | 0.41 | 0.41 | 0.41 | 0.39 | 0.42 | 0.43 | 0.44 | 0.43 | 0.44 | 0.44 | 0.45 | 0.44 | 0.40 | 0.42 | 0.45 | ||||||
| Vertex Pharmaceuticals Inc. | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q3 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= 62,671 ÷ 151,672 = 0.41
2 Click competitor name to see calculations.
The solvency profile exhibits a distinct structural shift in leverage beginning in mid-2023. Prior to this period, the entity maintained a relatively low and stable debt-to-capital ratio, which experienced a sharp ascent before consolidating at a higher plateau through the end of the observed period.
- Total Debt Trends
- A substantial increase in total debt is observed between April 2, 2023, and July 2, 2023, where obligations rose from 35,892 million USD to 65,341 million USD. Debt levels peaked at 71,888 million USD on December 31, 2023, followed by a gradual deleveraging trend. From December 2024 through September 2026, total debt remained relatively stable, fluctuating within a range of 61,712 million USD to 64,795 million USD.
- Total Capital Fluctuations
- Total capital showed a corresponding increase in mid-2023, rising from 136,862 million USD in April to 164,360 million USD in July. Following this peak, the capital base experienced moderate volatility, generally maintaining a range between 148,384 million USD and 161,821 million USD from 2024 through 2026.
- Debt to Capital Ratio Analysis
- The debt to capital ratio transitioned from a low-leverage regime, ranging between 0.26 and 0.32 from April 2022 to April 2023, to a higher-leverage regime. The ratio climbed sharply to 0.40 in July 2023 and reached a maximum of 0.45 by December 31, 2023. For the remainder of the period through September 2026, the ratio stabilized, oscillating between 0.40 and 0.44, suggesting a permanent shift in the long-term capital structure.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Debt to Assets
| Sep 27, 2026 | Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings, including current portion of long-term debt | 2,674) | 2,699) | 3,890) | 3,154) | 4,303) | 4,295) | 4,470) | 6,946) | 9,699) | 11,944) | 8,232) | 10,350) | 2,548) | 3,985) | 4,188) | 2,945) | 4,040) | 5,990) | 645) | ||||||
| Long-term debt, excluding current portion | 59,997) | 60,495) | 60,565) | 61,641) | 57,409) | 57,502) | 57,639) | 57,405) | 58,002) | 57,506) | 61,307) | 61,538) | 61,048) | 61,356) | 31,704) | 32,884) | 32,629) | 34,294) | 35,656) | ||||||
| Total debt | 62,671) | 63,194) | 64,455) | 64,795) | 61,712) | 61,797) | 62,109) | 64,351) | 67,701) | 69,450) | 69,539) | 71,888) | 63,596) | 65,341) | 35,892) | 35,829) | 36,669) | 40,284) | 36,301) | ||||||
| Total assets | 204,544) | 201,131) | 207,618) | 208,160) | 208,731) | 206,095) | 208,028) | 213,396) | 219,476) | 216,193) | 221,095) | 226,501) | 215,021) | 220,168) | 195,617) | 197,205) | 194,350) | 195,290) | 183,841) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | 0.31 | 0.31 | 0.31 | 0.31 | 0.30 | 0.30 | 0.30 | 0.30 | 0.31 | 0.32 | 0.31 | 0.32 | 0.30 | 0.30 | 0.18 | 0.18 | 0.19 | 0.21 | 0.20 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 0.55 | 0.52 | 0.53 | 0.50 | 0.51 | 0.51 | 0.51 | 0.50 | 0.50 | 0.50 | 0.50 | 0.44 | 0.45 | 0.45 | 0.46 | 0.46 | 0.49 | 0.51 | 0.51 | ||||||
| Amgen Inc. | 0.56 | 0.60 | 0.62 | 0.60 | 0.61 | 0.64 | 0.64 | 0.65 | 0.66 | 0.69 | 0.69 | 0.67 | 0.67 | 0.68 | 0.69 | 0.60 | 0.61 | 0.62 | 0.62 | ||||||
| Bristol-Myers Squibb Co. | 0.48 | 0.49 | 0.51 | 0.50 | 0.51 | 0.52 | 0.54 | 0.54 | 0.53 | 0.55 | 0.56 | 0.42 | 0.41 | 0.40 | 0.40 | 0.41 | 0.40 | 0.42 | 0.44 | ||||||
| Danaher Corp. | 0.28 | 0.29 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 | 0.22 | 0.22 | 0.22 | 0.22 | 0.25 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.26 | ||||||
| Eli Lilly & Co. | 0.33 | 0.39 | 0.37 | 0.38 | 0.37 | 0.40 | 0.43 | 0.43 | 0.41 | 0.40 | 0.41 | 0.39 | 0.35 | 0.34 | 0.36 | 0.33 | 0.33 | 0.36 | 0.35 | ||||||
| Gilead Sciences Inc. | 0.51 | 0.53 | 0.39 | 0.42 | 0.43 | 0.45 | 0.44 | 0.45 | 0.43 | 0.44 | 0.45 | 0.40 | 0.40 | 0.40 | 0.41 | 0.40 | 0.40 | 0.42 | 0.42 | ||||||
| Johnson & Johnson | 0.23 | 0.24 | 0.27 | 0.24 | 0.24 | 0.26 | 0.27 | 0.20 | 0.20 | 0.23 | 0.20 | 0.18 | 0.18 | 0.24 | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | ||||||
| Merck & Co. Inc. | 0.41 | 0.42 | 0.38 | 0.36 | 0.32 | 0.30 | 0.30 | 0.32 | 0.32 | 0.34 | 0.32 | 0.33 | 0.33 | 0.35 | 0.29 | 0.28 | 0.28 | 0.30 | 0.30 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | ||||||
| Thermo Fisher Scientific Inc. | 0.36 | 0.38 | 0.38 | 0.36 | 0.35 | 0.35 | 0.35 | 0.32 | 0.35 | 0.36 | 0.37 | 0.35 | 0.36 | 0.36 | 0.37 | 0.35 | 0.32 | 0.33 | 0.36 | ||||||
| Vertex Pharmaceuticals Inc. | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q3 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= 62,671 ÷ 204,544 = 0.31
2 Click competitor name to see calculations.
The solvency profile reflects a distinct two-phase trend characterized by an initial period of low leverage followed by a significant structural increase in debt levels that stabilized over the subsequent years.
- Debt to Assets Ratio Trend
- Between April 2022 and April 2023, the debt-to-assets ratio remained relatively low, fluctuating within a narrow band between 0.18 and 0.21. A sharp inflection point occurred in July 2023, where the ratio rose to 0.30, eventually peaking at 0.32 by December 31, 2023. From March 2024 through September 2026, the ratio exhibited high stability, maintaining a consistent range between 0.30 and 0.31.
- Debt and Asset Dynamics
- The increase in the solvency ratio was primarily driven by a substantial rise in total debt, which increased from 35,892 million USD in April 2023 to 65,341 million USD in July 2023. While total assets also increased during this period, reaching a peak of 226,501 million USD in December 2023, the growth in liabilities outpaced asset accumulation, leading to the observed increase in leverage.
- Long-term Stabilization
- Throughout 2024 and 2026, total debt experienced a gradual downward trajectory from its peak, declining from 69,539 million USD in March 2024 to 62,671 million USD by September 2026. Simultaneously, total assets underwent a moderate contraction from 221,095 million USD to 204,544 million USD. The proportional decrease in both total debt and total assets resulted in the maintenance of a steady debt-to-assets ratio of approximately 0.31.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Financial Leverage
| Sep 27, 2026 | Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Total assets | 204,544) | 201,131) | 207,618) | 208,160) | 208,731) | 206,095) | 208,028) | 213,396) | 219,476) | 216,193) | 221,095) | 226,501) | 215,021) | 220,168) | 195,617) | 197,205) | 194,350) | 195,290) | 183,841) | ||||||
| Total Pfizer Inc. shareholders’ equity | 89,001) | 85,190) | 90,101) | 86,476) | 92,801) | 88,695) | 90,338) | 88,203) | 92,286) | 87,700) | 92,282) | 89,014) | 96,934) | 99,019) | 100,970) | 95,661) | 92,631) | 87,208) | 82,424) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | 2.30 | 2.36 | 2.30 | 2.41 | 2.25 | 2.32 | 2.30 | 2.42 | 2.38 | 2.47 | 2.40 | 2.54 | 2.22 | 2.22 | 1.94 | 2.06 | 2.10 | 2.24 | 2.23 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | 95.89 | 40.65 | 23.78 | 20.94 | 18.59 | 13.00 | 11.26 | 10.52 | 10.14 | 8.04 | 8.84 | 9.77 | 8.80 | ||||||
| Amgen Inc. | 6.69 | 8.18 | 10.07 | 10.46 | 9.37 | 11.83 | 14.40 | 15.63 | 12.07 | 15.34 | 18.51 | 15.59 | 11.83 | 13.31 | 16.59 | 17.79 | 17.44 | 24.51 | 64.62 | ||||||
| Bristol-Myers Squibb Co. | 3.79 | 3.93 | 4.31 | 4.87 | 5.22 | 5.43 | 5.32 | 5.67 | 5.46 | 5.56 | 6.01 | 3.23 | 3.15 | 2.92 | 2.96 | 3.12 | 3.01 | 3.08 | 3.26 | ||||||
| Danaher Corp. | 1.74 | 1.76 | 1.58 | 1.59 | 1.56 | 1.56 | 1.56 | 1.57 | 1.57 | 1.57 | 1.56 | 1.58 | 1.67 | 1.64 | 1.65 | 1.68 | 1.72 | 1.76 | 1.80 | ||||||
| Eli Lilly & Co. | 3.68 | 4.20 | 3.74 | 4.24 | 4.83 | 5.52 | 5.67 | 5.55 | 5.31 | 5.30 | 4.99 | 5.94 | 5.16 | 4.95 | 4.75 | 4.65 | 4.71 | 5.51 | 5.03 | ||||||
| Gilead Sciences Inc. | 3.94 | 4.17 | 2.39 | 2.60 | 2.72 | 2.83 | 2.95 | 3.05 | 2.95 | 2.93 | 3.21 | 2.72 | 2.80 | 2.95 | 2.95 | 2.97 | 2.97 | 3.11 | 3.17 | ||||||
| Johnson & Johnson | 2.42 | 2.37 | 2.47 | 2.44 | 2.43 | 2.46 | 2.48 | 2.52 | 2.54 | 2.53 | 2.46 | 2.44 | 2.33 | 2.55 | 2.77 | 2.44 | 2.35 | 2.33 | 2.39 | ||||||
| Merck & Co. Inc. | 2.96 | 3.10 | 2.80 | 2.60 | 2.50 | 2.40 | 2.38 | 2.53 | 2.64 | 2.58 | 2.62 | 2.84 | 2.59 | 2.70 | 2.30 | 2.37 | 2.41 | 2.48 | 2.61 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.33 | 1.32 | 1.30 | 1.30 | 1.30 | 1.28 | 1.28 | 1.29 | 1.28 | 1.28 | 1.27 | 1.27 | 1.29 | 1.28 | 1.28 | 1.29 | 1.29 | 1.32 | 1.32 | ||||||
| Thermo Fisher Scientific Inc. | 2.09 | 2.15 | 2.18 | 2.07 | 2.02 | 2.00 | 2.01 | 1.96 | 2.05 | 2.08 | 2.13 | 2.11 | 2.14 | 2.15 | 2.24 | 2.21 | 2.08 | 2.14 | 2.26 | ||||||
| Vertex Pharmaceuticals Inc. | 1.57 | 1.35 | 1.37 | 1.37 | 1.44 | 1.40 | 1.39 | 1.37 | 1.42 | 1.36 | 1.29 | 1.29 | 1.32 | 1.32 | 1.31 | 1.30 | 1.28 | 1.31 | 1.31 | ||||||
Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q3 2026 Calculation
Financial leverage = Total assets ÷ Total Pfizer Inc. shareholders’ equity
= 204,544 ÷ 89,001 = 2.30
2 Click competitor name to see calculations.
The capital structure exhibits a period of asset expansion and equity growth followed by a phase of stabilization and slight contraction. Total assets grew from 183,841 million USD in April 2022 to a peak of 226,501 million USD in December 2023, before gradually moderating to 204,544 million USD by September 2026.
- Shareholders' Equity Dynamics
- Equity levels showed an initial upward trend, rising from 82,424 million USD in April 2022 to a peak of 100,970 million USD in April 2023. Subsequent periods were characterized by higher volatility, with equity fluctuating between 85,190 million USD and 92,801 million USD. This movement suggests a period of capital reallocation or changes in retained earnings following the early 2023 peak.
- Financial Leverage Trends
- The financial leverage ratio transitioned through three distinct stages. First, a deleveraging phase occurred between April 2022 and April 2023, where the ratio declined from 2.23 to a low of 1.94. Second, a significant spike in leverage was observed in late 2023, reaching a maximum of 2.54 in December 2023, driven by the simultaneous peak in total assets and a decrease in shareholders' equity. Third, from 2024 through September 2026, the ratio stabilized, oscillating within a range of 2.30 to 2.47.
- Solvency and Structural Analysis
- The overall trend indicates a shift from a conservative equity-heavy position in early 2023 toward a more leveraged structure by the end of 2023. The subsequent stabilization of the leverage ratio around 2.30 through 2026 suggests a strategic effort to maintain a consistent debt-to-equity balance while managing a stabilized asset base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?